Podcasts about asco annual meeting

Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42) Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23) Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01) Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22) Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37) CME information and select publications

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: Introduction (0:00) The Biopathophysiology of Myelofibrosis (MF) (2:19) Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49) Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00) Upcoming at European Hematology Association (EHA) 2026 (49:22) CME information and select publications

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics: Introduction (0:00) Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17) Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24) Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28) Management of Limited-Stage SCLC — Dr Ganti (1:31:54) CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics: Introduction (0:00) HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08) Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54) Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39) CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24) CME information and select publications

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute, in Washington, DC.Their discussion centered on the continued evolution of precision medicine in non–small cell lung cancer (NSCLC), highlighting advances in molecular testing, targeted therapies, immunotherapy, and emerging treatment strategies presented at the 2026 ASCO Annual Meeting. Drs Park and Liu explored how lung cancer has become a model for precision oncology and emphasized that therapeutic advances across multiple tumor types have collectively shaped the current treatment landscape. They discussed the importance of understanding oncogenic drivers, overcoming resistance mechanisms, and moving effective therapies into earlier-stage disease to improve long-term patient outcomes.

In today's episode, we spoke with Solange Peters, MD, PhD. Dr Peters is a full professor, and chair of medical oncology and the thoracic malignancies programme in the Department of Oncology at the University Hospital of Lausanne in Switzerland. In our exclusive interview, Dr Peters discussed the rationale for pairing antiangiogenic activity with checkpoint inhibition upfront in non–small cell lung cancer (NSCLC), rather than sequencing them. She noted that prior attempts to combine or sequence bevacizumab (Avastin) with checkpoint inhibitors yielded only modest signals, hampered by bevacizumab's long half-life and class-specific toxicities including bleeding risk that historically excluded patients with squamous cell carcinoma. By contrast, PD-L1/VEGF bispecifics such as pumitamig carry a significantly shorter half-life of approximately 5 to 6 days, resulting in a similar toxicity category but with lower rates of high-grade events and a broadened eligible population.She highlighted the mechanistic rationale for this combination, explaining that VEGF and PD-L1 co-targeting appears to remodel the tumor microenvironment cooperatively, bringing cancer cells into closer proximity with T cells. In the case of PD-L1/VEGF bispecifics, a macromolecular structure forms in the tumor microenvironment that leads to internalization of PD-L1, creating a dual blockade of the PD-1/PD-L1 pathway beyond simple receptor occupancy.Dr Peters then discussed data presented at the 2026 ASCO Annual Meeting from the phase 2/3 ROSETTA Lung-02 trial (NCT06712316) evaluating pumitamig plus chemotherapy in the first-line setting. She described the activity observed across all PD-L1 expression strata, including in PD-L1–negative patients, who comprised up to 70% of the nonsquamous population and achieved response rates above 50% as particularly compelling. She also addressed the dose selection rationale, noting that the 1500-mg dose demonstrated the optimal pharmacodynamic activity and favorable risk-benefit profile for phase 3 advancement.Finally, Dr Peters offered broader perspective on the increasingly competitive PD-L1/VEGF bispecific landscape, including the parallel development of ivonescimab. She suggested that differences in clinical trial design including patient population, inclusion and exclusion criteria, and end point ambition may ultimately differentiate agents more than mechanism alone, and emphasized that global data will be essential to shaping regulatory and clinical practice decisions.

In today's episode, we spoke with Tanios S. Bekaii-Saab, MD. Dr Bekaii-Saab is the David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I, at the Mayo Clinic College of Medicine and Science, the division chair of Hematology/Medical Oncology at Mayo Clinic, and co-leader of the Advanced Clinical and Translational Science Program and the disease group leader for Gastrointestinal Cancers for the Mayo Clinic Comprehensive Cancer Center in Phoenix, Arizona.In our exclusive interview, Dr Bekaii-Saab discussed findings from the final analysis of cohort 3 of the phase 3 BREAKWATER trial (NCT04607421), which were presented at the 2026 ASCO Annual Meeting. These data showed that encorafenib (Braftovi) plus cetuximab (Erbitux) and FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan) significantly improved outcomes compared with standard of care in patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC), building on previously reported data from the trial that led to the February 2026 full FDA approval of encorafenib plus cetuximab and modified FOLFOX6 (leucovorin calcium, fluorouracil, and oxaliplatin) for this patient population. He also highlighted promising bispecific agents targeting VEGF and PD-1, as well as the promise of KRAS G12C inhibitors like calderasib (MK-1084) and sotorasib (Lumakras). Finally, he emphasized that minimal residual disease testing is prognostic and potentially predictive, and can aid in personalized mCRC management.

Send us Fan MailWhat were some of the biggest metastatic breast cancer updates from the 2026 ASCO Annual Meeting and which findings are already changing care?In this episode of OUR MBC Life, Dr. Chen breaks down key research findings and what they mean for people living with metastatic breast cancer. This episode also includes a Q & A featuring questions from our community about treatment,  side effects and what these new advances mean for people living with metastatic breast cancer.We're so happy you joined us! If this conversation resonated with you please share it with someone who might need it. Don't forget to like and subscribe here to follow us on your favorite podcast platform so you never miss an episode. You can find more episodes, resources and ways to get involved on our website Our MBC Life. Have a topic you'd like us to cover? Email us at ourmbclife@sharecancersupport.org. And don't forget to follow us on our socials @ourmbclife. Remember you are not alone.

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Stacey A Cohen and Dr Arvind Dasari, moderated by Dr Bekaii-Saab, including the following topics: Introduction (0:00) Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Localized and Locally Advanced Colorectal Cancer (CRC) — Dr Cohen (1:45) Clinical Relevance and Practical Utilization of Molecular Residual Disease Analysis in CRC — Dr Dasari (34:08) Recent Advances in Metastatic CRC: Optimizing Immunotherapy and Other Approaches — Dr Bekaii-Saab (1:00:42) CME information and select publications

In today's episode, we spoke with Paolo Tarantino, MD, PhD. Dr Tarantino is a breast medical oncologist and advanced fellow at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts.In our exclusive interview, Dr Tarantino discussed practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting, including the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta) for first-line treatment of HER2-positive breast cancer based on findings from the phase 3 DESTINY-Breast09 trial (NCT04784715); updated safety data from the phase 3 DESTINY-Breast05 trial (NCT04622319) that indicated that T-DXd–associated interstitial lung disease is reversible with steroids, although radiation pneumonitis is non-reversible; and the phase 3 OPTIMA trial (ISRCTN42400492) results, which suggested that the PAM50 signature can identify patients who may not need chemotherapy, potentially sparing them from unnecessary treatment.

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O'Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics: Introduction (0:00) Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35) Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O'Shaughnessy (25:23) Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06) Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17) CME information and select publications

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, joins presenters to honor the winners of Healio's 2026 Disruptive Innovators Awards in hematology and oncology. ·       VK Gadi, MD, PhD, presents the Heath Equity Award to Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES. 2:13 ·       Hansa Bhargava, MD, presents the Lifetime Disruptor Award to Ann H. Partridge, MD, MPH. 4:33 ·       Hansa Bhargava, MD, presents the Healio NextGen Disruptor Award to Colton Frisco Jones, MD. 7:22 ·       Morgan Collier presents the Woman Disruptor of the Year Award to Erin N. Kobetz, PhD, MPH.  9:43 ·       Richard T. Lee, MD, from City of Hope, accepts the Clinical Innovation Award for the National Clinical Trials System. 11:55 ·       Ryne Wilson, DNP, RN, OCN, presents the Advanced Practice Trailblazer Award to Stacy J. Hines-Dowell, DNP, ACGN, FNP-BC, AGN-BC. 14:43 ·       Diana Gelston presents the Patient Voice Award to Crossroads4Hope and its CEO, Amy Sutton. 16:35 ·       Karine Tawagi, MD, presents the Social Media Influencer Award to Eric K. Singhi, MD. 19:26 ·       Justin McDonnell of Johnson & Johnson accepts the Healio Industry Breakthrough Award for Darzalex Faspro (daratumumab and hyaluronidase-fihj). 21:49 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. To learn more about Healio Disruptive Innovators, visit Healio.com/Innovators. Jain reports no relevant financial disclosures.

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics: Introduction (0:00) Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45) Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55) Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42) Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24) CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (00:00) Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27) EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08) Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16) Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08) Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46) CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Introduction (00:00) Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50) Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15) Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41) CME information and select publications

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics: Introduction (00:00) Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40) Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41) Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12) Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35) Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39) CME information and select publications

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with Erin Gillaspie, MD, MPH, and Laurie Matt-Amaral, MD, MPH, about navigating challenges as women in oncology, investing in relationships and more. ·       Gillaspie and Matt-Amaral share their journeys within their fields. 2:37 ·       Have you ever experienced imposter syndrome? 9:26 ·       How did you navigate moments when it felt like you had hit a wall? 10:36 ·       How have you balanced family life and your career? 21:25 ·       If you had to give two or three tips for up-and-coming women physicians, what would they be? 30:07 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Gillaspie can be reached at eringillaspie@creighton.edu or on Instagram @dreringillaspie. Matt-Amaral can be reached at mattaml@ccf.org. Jain reports no relevant financial disclosures. Gillaspie reports consulting or speakers bureau roles with and/or travel, accommodations and expenses from AstraZeneca, Bristol Myers Squibb, Genentech, Intuitive Surgical and Merck. Matt-Amaral reports research funding to her institution from Agendia.

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics: Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00) - Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41) - Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23) - Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48) CME information and select publications

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics: Introduction (00:00) Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57) Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01) Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36) Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36) Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10) CME information and select publications

Dr. Megan Kruse and Dr. Hope Rugo discuss practice-changing data in metastatic breast cancer and critical shifts in the treatment of early-stage disease that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT

In this episode, Shikha Jain, MD, speaks with Revolution Medicines' Alan Sandler, MD, about groundbreaking advancements with daraxonrasib and how these findings will continue to impact metastatic pancreatic cancer. Daraxonrasib (RMC-6236, Revolution Medicines) is an investigational, oral pan-RAS inhibitor in development for treatment of advanced solid tumors, including pancreatic ductal adenocarcinoma. ·       Why the RASolute 302 trial got a standing ovation at ASCO. 3:16 ·       What do you think changed scientifically to make this particular drug and its results possible? 6:12 ·       What does the multi-selective RAS inhibition of this drug mean, and how does it differ from other drugs? 10:23 ·       How would you recommend navigating the early access program (EAP) for patients and physicians who want this drug now? 13:13 ·       What excites you about the future of pancreatic cancer and RAS treatment? 14:18 ·       How can you imagine when these drugs will get into the hands of patients if we see good results? 17:28 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Sandler can be reached via email at inquiries@revmed.com. Reference: ·        Wolpin BM, et al. LBA5. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. Jain and Sandler report no relevant financial disclosures.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss high-impact abstracts in the treatment of prostate, bladder, and kidney cancers that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT

Dr. Pauline Funchain and Dr. Allison Betof discuss practice-changing and paradigm-shifting abstracts in melanoma, Merkel cell carcinoma, and cellular therapies that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT

Dr. Nilo Azad and Dr. Aparna Parikh discuss high-impact studies in gastrointestinal cancers and other novel treatment approaches that were presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT

In deze podcast kunt u luisteren naar het gesprek van internist-oncoloog Koos van der Hoeven en internist-oncoloog Debbie Robbrecht, werkzaam in het Erasmus MC te Rotterdam. Aan bod komen de laatste ontwikkelingen met betrekking tot de behandeling van blaas- en niercarcinoom gepresenteerd tijdens de 2026 ASCO Annual Meeting.

Dr. Marc Braunstein and Dr. Adam Kittai highlight top research on hematologic malignancies from the 2026 ASCO Annual Meeting, including studies on lymphoid malignancies, multiple myeloma, and plasma cell disorders. LINK TO FULL TRANSCRIPT  

Dr. Christine Lovly and Dr. Vamsi Velcheti discuss practice-changing lung cancer data presented at the 2026 ASCO Annual Meeting, including key studies on squamous cell lung cancer, NSCLC, and SCLC. LINK TO FULL TRANSCRIPT

Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer.

In deze podcast kunt u luisteren naar het gesprek van internist-oncoloog Koos van der Hoeven en longarts Lizza Hendriks werkzaam in het Maastricht UMC+. Aan bod komen de laatste ontwikkelingen met betrekking tot de behandeling van longkanker gepresenteerd tijdens de 2026 ASCO Annual Meeting.

In deze podcast kunt u luisteren naar het gesprek van internist-oncoloog Koos van der Hoeven en internist-oncoloog Agnes Jager werkzaam in het Erasmus MC te Rotterdam. Aan bod komen de laatste ontwikkelingen met betrekking tot de behandeling van borstkanker gepresenteerd tijdens de 2026 ASCO Annual Meeting.

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with W. Kimryn Rathmell, MD, PhD, about the new and evolving ways cancer care is delivered, building networks through advocacy and more. ·       Who is Dr. W. Kimryn Rathmell?  2:17 ·       Jain and Rathmell discuss the need for physician scientists in administrative leadership. 11:37 ·       How do you think networks and communities can impact careers? 17:08 ·       What are your thoughts on using social media in the cancer space? 22:35 ·       How do you think AI is going to transform the way we deliver care? 26:21 ·       As you have navigated your career, how have you approached challenges around being a woman in leadership roles? 29:29 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Rathmell can be reached on LinkedIn. Jain reports no relevant financial disclosures. Rathmell reports a relationship with Interact Therapeutics, as well as institution relationships with Merck and Sitryx.

Welcome to the Patient from Hell podcast! Live from ASCO 2026, we explore breakthroughs in clinical oncology, cancer research, AI healthcare tools, and targeted therapy for advanced cancer.Samira Daswani, Founder and CEO of Manta Cares and host of The Patient From Hell, sits down with Dr. Doug Blayney, Chief Medical Officer of Manta Cares and former ASCO President, for a candid debrief in between sessions at the 2026 ASCO Annual Meeting in Chicago.With 45,000 oncology professionals in attendance, ASCO is the largest gathering of cancer researchers and clinicians in the world. In this episode, Samira and Dr. Blayney break down what actually mattered: the clinical findings, the shifting treatment landscape, and what the research trends mean for patients navigating cancer today.This episode is for oncologists, cancer researchers, and anyone who wants to understand where the field is heading.Topics covered, with more to come in our next episode:Key clinical findings from ASCO 2026Trends shaping experimental and clinical oncologyWhat high attendance and collaboration signals for the future of cancer researchWhat patients should know coming out of this year's conferenceCHAPTERS:0:00 - ASCO 2026 Annual Meeting Live from Chicago0:27 - Artificial Intelligence (AI) in Oncology & Patient Experience1:19 - Healthcare AI Challenges: Misinformation & Clinician Deskilling2:03 - Pancreatic Cancer Breakthrough: New RAS/KRAS Targeted Therapy2:30 - Lung Cancer Advancements: ALK Mutations & PD-L1 Data3:01 - Breast Cancer Innovation: Oral SERDs & ESR1 Biomarkers3:41 - Next Episode Preview & Wrap UpSubscribe for frequent breakdowns of cancer research, treatment news, patient stories, and guidance and support for people in treatment for cancer. Drop a comment with the topics or trials you want us to cover next!

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape. Guests: Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of data from the phase 3 RASolute 302 trial (NCT06625320), a landmark study presented at the 2026 ASCO Annual Meeting that has established daraxonrasib (RMC-6236) as the new standard of care (SOC) for the second-line treatment of patients with metastatic pancreatic adenocarcinoma.The discussion began by highlighting the historical context of second-line treatment, where standard chemotherapy options like FOLFOX (leucovorin calcium, fluorouracil, and oxaliplatin) or gemcitabine-based regimens typically yielded a median overall survival (OS) of only approximately 6 to 7 months. Although RAS mutations drive approximately 90% of pancreatic cancers, they were historically considered undruggable. Daraxonrasib addresses this challenge with its mechanism of action of an oral, RAS(ON), multi-selective, tri-complex inhibitor that targets the active GTP-bound state of both mutant and wild-type RAS, covering variants at codons G12, G13, and Q61.The RASolute 302 trial was an international, open-label study that randomly assigned patients with progression after 1 prior line of therapy to receive either daaxonrasib or investigator's choice of chemotherapy. In the RAS G12–mutated subpopulation of patients, daraxonrasib generated a higher median OS compared with chemotherapy. Similar benefits were observed with daraxonrasib in the overall population, where the median progression-free survival nearly doubled.Drs Armstrong and Tawagi emphasized that the toxicities associated with daraxonrasib are highly clinically relevant and distinct from the myelosuppression seen with chemotherapy. Key adverse effects (AEs) include dermatologic events, diarrhea, and stomatitis. Management of these AEs is critical; the hosts recommended the use of prophylactic oral antibiotics and topical corticosteroids to manage rash, alongside standard oral care for mucositis. Despite being associated with these AEs, daraxonrasib was better tolerated than chemotherapy, with a low treatment discontinuation rate due to AEs.Daraxonrasib is currently accessible in the US through an Expanded Access Program and is undergoing accelerated review for full FDA approval. The experts noted that the agent is being further investigated in the frontline setting through the phase 3 RASolute 303 trial (NCT07491445) and in the adjuvant setting via the phase 3 RASolute-304 trial (NCT07252232), potentially expanding the agent's effect across the continuum of pancreatic cancer care.

In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages. Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO

Dr. Aly-Khan Lalani and Dr. Chris Wallis dive into the latest bladder cancer breakthroughs, starting with crucial long-term updates from the landmark EV-302 trial. They share encouraging survival data for patients, while exploring which treatments work best if the cancer eventually progresses. The doctors also discuss the future of localized disease, reviewing strategies from the POTOMAC and SAKK trials. By highlighting a range of advanced monitoring tools, they map out how modern care is helping patients safely avoid major surgery while maintaining excellent disease control.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.

Dr. Aly-Khan Lalani and Dr. Chris Wallis discuss how new data from the RAMPART trial strengthens the argument for administering  immune-boosting therapies to patients after surgery. This episode also touches on the human side of cancer care, exploring new ways to measure patient side effects and reduce post-treatment regret through improved  counseling. The doctors finish the conversation by highlighting a promising new combination of repurposed drugs that is offering renewed hope to young patients fighting Renal Medullary Carcinoma.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Recorded in Chicago, Dr. Aly-Khan Lalani and Dr. Chris Wallis unpack a massive slate of prostate cancer data, fresh from the 2026 ASCO Annual Meeting. The conversation spans the entire disease spectrum, beginning with a deep dive into the PROTEUS trial. Shifting to advanced disease, Dr. Lalani and Dr. Wallis discuss the TALAPRO-3 and the A-DREAM/Alliance A032101 trials. Concluding with a review of sequencing chemotherapy and radioligand therapy in the PLUDO trial, this episode provides an excellent overview of the prostate cancer landscape presented at ASCO 2026.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

In deze podcast kunt u luisteren naar het gesprek van internist-oncoloog Koos van der Hoeven en internist-oncoloog Hanneke van Laarhoven, werkzaam in het Amsterdam UMC. Aan bod komen de laatste ontwikkelingen met betrekking tot de behandeling van upper GI-tumoren gepresenteerd tijdens de 2026 ASCO Annual Meeting.

In deze podcast kunt u luisteren naar het gesprek van internist-oncoloog Koos van der Hoeven en internist-oncoloog Jeanine Roodhart werkzaam in het UMC Utrecht. Aan bod komen de laatste ontwikkelingen met betrekking tot de behandeling van colorectale tumoren gepresenteerd tijdens de 2026 ASCO Annual Meeting.

In deze podcast kunt u luisteren naar het gesprek van internist-oncoloog Koos van der Hoeven en internist-oncoloog André Bergman, werkzaam in het Antoni van Leeuwenhoek te Amsterdam. Aan bod komen de laatste ontwikkelingen met betrekking tot de behandeling van prostaatcarcinoom gepresenteerd tijdens de 2025 ASCO Annual Meeting.

In deze podcast kunt u luisteren naar het gesprek van internist-oncoloog Koos van der Hoeven en internist-oncoloog Astrid van der Veldt werkzaam in het Erasmus MC te Rotterdam. Aan bod komen de laatste ontwikkelingen met betrekking tot de behandeling van melanoom gepresenteerd tijdens de 2026 ASCO Annual Meeting.

Dr. Monty Pal shares highlights from Day 4 of the 2026 ASCO Annual Meeting, including a much-anticipated study in hepatocellular carcinoma, new data in non–small cell lung cancer, and a key update in the treatment of Merkel cell carcinoma. LINK TO TRANSCRIPT

Dr. Monty Pal shares highlights from Day 3 of the 2026 ASCO Annual Meeting, including new research for the treatment of advanced CRC and mCRPC, TIL cell therapy in advanced non-uveal melanoma, and an ultra-low dose immunotherapy trial in head and neck squamous cell carcinoma. LINK TO FULL TRANSCRIPT

Dr. Monty Pal shares highlights from Day 2 of the 2026 ASCO Annual Meeting, including a practice-changing trial in renal cell carcinoma, advances in ER-positive, HER2-negative early breast cancer, and the use of olanzapine as an effective steroid-sparing alternative for chemo-induced nausea and vomiting in pediatric cancer. LINK TO FULL TRANSCRIPT

In the first episode of a special daily series during the 2026 ASCO Annual Meeting, Dr. Monty Pal discusses 3 abstracts, including a follow-up on the EV-302 study in urothelial carcinoma, a potential new treatment option for patients with PD-L1-positive advanced non–small cell lung cancer, and a novel psychosocial digital application that improves fatigue and distress in patients with multiple myeloma. LINK TO FULL TRANSCRIPT

Dr. Lyudmila Bazhenova joins the podcast to share the update to the living guideline on stage IV NSCLC without driver alterations. Dr. Bazhenova discusses the evidence reviewed for both non-squamous NSCLC, including the POD1IM-304 and BAP BRAIN trials, and squamous cell NSCLC, including the HARMONi-6 trial. She shares how these results impacted the clinical practice guideline, what they mean for patients receiving immunotherapy and chemotherapy, and where the panel is waiting for additional evidence to clarify the role of therapeutic options. Dr. Bazhenova encourages listeners to stay tuned for future updates to the living guideline after publication of data from the 2026 ASCO Annual Meeting. Read the full living guideline "Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations, ASCO Living Guideline Version 2026.3.1" LINK TO FULL TRANSCRIPT

Today we will be focusing on exciting data to come at the ASCO Annual Meeting in 2026 in Chicago, with a special focus on GU sessions, educational sessions & med ed sessions.

Dr. Monty Pal and Dr. Jo Chien preview new research, hot topics, and emerging innovations in oncology that will be presented at the 2026 ASCO Annual Meeting. LINK TO FULL TRANSCRIPT